Stanford Cancer Institute — Stanford, California

Public research footprint of Stanford Cancer Institute, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Non-small Cell Lung Cancer · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer · KRAS G12C-mutated Solid Tumors, Lung Cancer · Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Recently updated registry entries

NCT06128551 — Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in… (Recruiting)
NCT04996875 — (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis (Recruiting)
NCT06915753 — Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Stanford Cancer Institute?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 04, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.